论文部分内容阅读
目的:探讨二磷酸腺苷核糖基化因子6(ADP-ribosylation factor 6,ARF6)在肝细胞肝癌(简称肝癌)组织中的表达及临床意义。方法:收集肝癌手术切除标本150例,以癌旁肝硬化组织作对照,制作组织芯片,用组织芯片技术结合免疫组化法,检测肝癌组织和癌旁肝硬化组织ARF6的表达,探讨ARF6表达与临床病理特征及预后之间的关系。结果:肝癌组织中ARF6的阳性表达率为48.7%(73/150),在癌旁肝硬化组织中ARF6的阳性表达率为8.3%(4/48),两者比较差异有统计学意义(P<0.05)。肝癌组织中ARF6阳性表达与门静脉癌栓、临床分期、肿瘤直径及甲胎蛋白(AFP)水平相关(P<0.05)。ARF6表达阴性的肝癌患者在肝切除术后的无瘤中位存活时间为45个月,1、3、5年无瘤生存率分别为(93.22±7.93)%、(58.91±6.18)%、(24.59±6.80)%;ARF6表达阳性患者的无瘤中位存活时间为36个月,1、3、5年无瘤生存率分别为(88.91±3.70)%、(41.61±5.93)%、(19.03±4.94)%。ARF6表达阴性与表达阳性的肝癌患者的无瘤生存时间差异有统计学意义(P=0.019 1)。结论:肝癌组织中ARF6的表达与预后密切相关,ARF6不仅可作为肝癌预后不良的判断指标,还有望成为一种新的肝癌预后判断的标志物和潜在的治疗靶标。
Objective: To investigate the expression and clinical significance of ADP-ribosylation factor 6 (ARF6) in hepatocellular carcinoma (HCC). Methods: 150 cases of resected hepatocellular carcinoma (HCC) were collected. Tissue microarray was made with para-carcinoma of liver cirrhosis. The expression of ARF6 was detected by tissue microarray combined with immunohistochemistry. The relationship between clinicopathological features and prognosis. Results: The positive expression rate of ARF6 in hepatocellular carcinoma was 48.7% (73/150), and the positive expression rate of ARF6 in para-cancerous liver cirrhosis was 8.3% (4/48) (P <0.05). The positive expression of ARF6 in hepatocellular carcinoma was correlated with the degree of portal vein tumor thrombus, clinical stage, tumor diameter and AFP level (P <0.05). The median tumor-free survival after hepatectomy for ARF6-negative HCC patients was 45 months. The 1, 3, 5 year disease-free survival rates were (93.22 ± 7.93)% and (58.91 ± 6.18)%, respectively 24.59 ± 6.80)%. The median tumor-free survival of patients with positive ARF6 expression was 36 months. The 1, 3 and 5 year disease-free survival rates were (88.91 ± 3.70)% and (41.61 ± 5.93)%, respectively ± 4.94)%. The difference of tumor-free survival time between ARF6-negative and HCC-positive patients was statistically significant (P = 0.0191). CONCLUSIONS: The expression of ARF6 in hepatocellular carcinoma is closely related to the prognosis. ARF6 not only can be used as a prognostic indicator of poor prognosis of HCC, but also is expected to become a new marker and a potential therapeutic target for the prognosis of HCC.